Skip to content
HIGHLIFE MEDICAL
Menu
  • Home
  • About Us
    • Board of Directors
  • Mitral Valve Insufficiency
  • Technology
  • Healthcare Professionals
    • Physician Feedback
    • Publications
  • News
  • Contact

Author: HighLife

Clinicals

January 3, 2022 – HighLife’s TSMVR Technology successfully used for the first time in China

HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced …

HighLife Medical Logo
Clinicals

May 18, 2021 – HighLife’s TSMVR System and Clinical Study progress featured at EuroPCR 2021

HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from mitral regurgitation, announced today that several presentations will be …

Corporate

December 21, 2020 – Peijia Medical and HighLife Enter Into a License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology BEIJING and PARIS, December 21, 2020 – Peijia Medical Ltd (HK Stock Code: 09996) …

Corporate

December 11, 2020 – VI Partners invests in Highlife Medical

VI Partners proudly announces its investment into HighLife Medical. Highlife Medical develops a new 2-component (“valve in ring”) transcatheter mitral valve replacement systems offering unique features for the treatment of …

Corporate

January 17, 2019 – HighLife Closes a €32 Million Round B Financing

HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced today it had closed a € 32 …

Corporate

May 9, 2018 – HighLife appoints Dr. Martin Rothman as independent member of the board

HighLife SAS, a medtech company focused on the development of a unique trans- catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment …

Corporate

Dec. 8, 2017 – HighLife appoints Jose Calle Gordo as Chairman of the Board

HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of …

Corporate

Oct. 30, 2017 – HighLife closes €12.3 million financing round led by Sofinnova Partners

This financing allows for the acceleration of the company’s clinical and R&D program HighLife SAS, an early-stage medtech company focused on the development of a unique trans-catheter mitral valve replacement …

Clinicals

Sep. 22, 2017 – HighLife Successfully Initiates its Clinical Study in Europe

First 3 activated clinical centers in France enroll patients HighLife SAS announced today the start of its European clinical study with the enrollment of the first 3 patients at major …

Clinicals

Sep. 14, 2016 – HighLife successfully initiates its clinical feasibility phase

HighLife SAS announced today the successful treatment of 5 consecutive patients in its early feasibility clinical phase. The first three cases were carried out in Kiev (Ukraine) in the adult …

Copyright © 2023 HIGHLIFE MEDICAL – OnePress theme by FameThemes